| Trial ID: | L6762 |
| Source ID: | NCT00953498
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: pioglitazone|DRUG: rosiglitazone
|
| Outcome Measures: |
Primary: Action of glitazone on the endothelium-dependent vasodilatory effects of HDL lipoproteins, 6 months | Secondary: Effect of glitazone therapy on Phospholipase A2 level, 6 months|Analyze the glycemic response to glitazones according to baseline clinical and biological characteristics, 6 months|Look for possible differences between pioglitazone and rosiglitazone for their effects on HDL lipoproteins and phospholipase A2, 6 months
|
| Sponsor/Collaborators: |
Sponsor: Centre Hospitalier Universitaire Dijon
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-10
|
| Completion Date: |
2012-03
|
| Results First Posted: |
|
| Last Update Posted: |
2013-09-02
|
| Locations: |
Service Endocrinologie-diabétologie, Hôpital du Bocage CHU, Dijon, 21000, France
|
| URL: |
https://clinicaltrials.gov/show/NCT00953498
|
